To become a certified prescriber in the JYNARQUE REMS, you must: complete this Prescriber Knowledge Assessment and the Prescriber Enrollment Form. You must answer ALL eight questions correctly to become certified.

1. Review the following materials:
   - Prescribing Information
   - REMS Program Overview
   - Prescriber Training

2. Complete your name, NPI number and phone number and answer all 8 questions

3. Submit your completed Prescriber Knowledge Assessment and Prescriber Enrollment Form to the REMS online at www.JYNARQUErems.com or via fax at 1-866-750-6820

If completed via fax, you will be notified by the REMS on the status of your certification within 2 business days upon receipt. When contacted, you will receive either:
   - Confirmation of your certification in the REMS or
   - Instructions on how to retake the Prescriber Knowledge Assessment, if necessary

JYNARQUE® (tolvaptan) REMS PRESCRIBER KNOWLEDGE ASSESSMENT

*Indicates required field

Prescriber Information

First Name*: ___________________________ Middle Initial: _____ Last Name*: ___________________________
National Provider Identifier No. (NPI)*: ___________________________ Phone*: ___________________________
Email: ___________________________

Questions 1 – 8 Select the 1 best answer

Question 1
Before starting a new patient on JYNARQUE, I should
   - Read the U.S. Prescribing Information (USPI), Prescriber Training, and the REMS Program Overview
   - Counsel patients about the risk of serious and potentially fatal liver injury associated with JYNARQUE
   - Order and review baseline hepatic labs
   - All of the above

Question 2
Patients you identify as appropriate for JYNARQUE must enroll in the JYNARQUE REMS Program in order to be able to receive treatment ..........................................
   - True
   - False

Question 3
JYNARQUE is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD). ..........
   - True
   - False

Question 4
The primary counseling message I should tell my patients is:
   - Do not drink alcohol before you take JYNARQUE
   - Stop therapy if ALT or AST is >2 times the ULN
   - There is a risk of serious and potentially fatal liver injury associated with JYNARQUE and that blood testing and monitoring is required
   - Patients need to have blood tests every 18 months

Question 5
I will submit a Patient Status Form for each patient every 3 months for first 18 months of treatment and every 6 months thereafter. .................................................................
   - True
   - False

Question 6
I will educate my patients on JYNARQUE; the REMS; and the signs and symptoms of liver injury and what to do should they experience them, before I enroll them into the REMS. ...........
   - True
   - False

Question 7
Patients can take JYNARQUE and elect not to have blood tests done. ..............................................
   - True
   - False

Question 8
Only pharmacies enrolled in the REMS may dispense JYNARQUE to patients. ..............................................
   - True
   - False

Phone: 1-866-244-9446 | www.JYNARQUErems.com | Fax: 1-866-750-6820

Healthcare providers must report cases of liver injury to the REMS Program Coordinating Center.